6:10 PM
 | 
May 08, 2013
 |  BC Extra  |  Clinical News

Fish oil fails in large Phase III trial

Italian researchers reported that a once-daily 1 g dose of N-3 polyunsaturated fatty acids missed the primary endpoint in a Phase III trial in 12,513 patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who had not had a myocardial infarction (MI). The primary endpoint of the double-blind...

Read the full 223 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >